Canaccord Genuity analyst Richard Close maintained a Buy rating on Evolent Health (NYSE: EVH) yesterday and set a price target of $24. The company’s shares closed yesterday at $21.65.
Close wrote:
“We were previously unaware that Evolent had partnered with Nicklaus Children’s Health System to form Miami Children’s Health Plan.”
According to TipRanks.com, Close is a 5-star analyst with an average return of 14.1% and a 61.1% success rate. Close covers the Services sector, focusing on stocks such as Envision Healthcare, Premier Inc, and Maximus.
Currently, the analyst consensus on Evolent Health is Strong Buy and the average price target is $24.29, representing a 12.2% upside.
In a report issued on June 4, Piper Jaffray also initiated coverage with a Buy rating on the stock with a $30 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $27.50 and a one-year low of $10.30. Currently, Evolent Health has an average volume of 794.7K.
Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Evolent Health, Inc. engages in the provision of health care delivery and payment services. Its solutions include population health management, health plan administration and third party administration, network performance management, risk adjustment, pharmacy benefit management, analytics and performance improvement, and technology and electronic medical record integration. The company was founded by Frank J. Williams, Seth B. Blackley, and Tom Peterson in August 2011 and is headquartered in Arlington, VA.
